Form 4: Amgen Director Ellen Kullman Reports Acquisition of 809 Shares Through Incentive Program

Amgen Inc. Director Ellen Jamison Kullman reported the acquisition of 809 shares of common stock on May 23, 2025, as part of the company's Director Incentive Program.

Summary

• Amgen Inc. Director Ellen Jamison Kullman acquired 809 shares of Amgen common stock on May 23, 2025.
• The shares were acquired at a price of $0, indicating they were granted as Restricted Stock Units (RSUs) under the Amgen Inc. 2009 Director Incentive Program, as amended.
• These RSUs vested immediately upon grant and are paid in shares of the Company's common stock on a one-to-one basis, with the option for the director to defer payment according to an elected schedule.
• The reported beneficial ownership of Common Stock by Ms. Kullman following this transaction is 13,466.9807 shares.
• The total shares beneficially owned include 1,717 Dividend Equivalents (DEs) granted pursuant to the Director Program, which are credited on vested but deferred RSUs and paid out in shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director receiving equity compensation, aligning their interests with shareholders. It's a routine transaction, so not highly impactful, but generally viewed favorably as a sign of continued commitment.

Positives

• The acquisition of shares by a director aligns their financial interests with those of shareholders, potentially fostering a stronger commitment to long-term company performance.
• The grant is part of a structured and pre-approved incentive program (Amgen Inc. 2009 Director Incentive Program), indicating a routine and expected component of director compensation.

Negatives

• No specific negative points are identified in this routine Form 4 filing, which primarily reports an insider transaction.

Risks

• No specific risks are identified in this routine Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the company's future performance, as it is a routine insider transaction report.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock acquisition, common in the biotechnology and pharmaceutical industry as part of executive and director compensation packages. It reflects standard corporate governance practices for aligning director interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and Dividend Equivalents (DEs) to directors is a common practice across large-cap pharmaceutical and biotechnology companies, such as Pfizer, Johnson & Johnson, and Merck, as a component of their non-employee director compensation programs.
• The immediate vesting of RSUs for directors is also a standard feature in many such plans, aiming to provide immediate equity alignment.
• The specific value of the grant (809 shares at $0 cost) would need to be compared against the total compensation packages of directors at comparable companies to assess its relative size, but the mechanism itself is standard within the industry.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders through equity ownership, potentially fostering long-term value creation. It also represents a minor dilution from the issuance of new shares, though this is typical for equity compensation plans.
• Director (Ellen Jamison Kullman): The transaction represents a component of her compensation for serving on the board, providing her with direct equity in the company.

Next Steps

• The document does not outline specific future actions or milestones beyond the reported transaction.

Key Dates

Keywords

Amgen, AMGN, SEC Form 4, Insider Trading, Stock Grant, Restricted Stock Units, RSU, Director Compensation, Beneficial Ownership, Equity Incentive Plan